Bristol-Myers Squibb Co
Bristol Myers Squibb says Alzheimer’s is the biggest market for new schizophrenia drug
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue. In […]
Read More
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon from San Francisco! This week, Ashley and I are attending the annual JPMorgan Health Care Conference – the largest gathering of biotech and pharma execs, […]
Read More
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, August 29, 2020. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The U.S. Food and […]
Read More
Bargain hunting: These 8 portfolio stocks look quite cheap, but only some are worth buying
The holiday shopping season has come and gone. When it comes to stock picking, at least, the desire to find a bargain is as strong as ever. A recent analysis of our portfolio revealed we own more than a couple cheap stocks, including one of our newer additions in Bristol Myers Squibb . Still, we’re […]
Read More
We’re adding to our position in a stock that just landed a big Wall Street endorsement
Shortly after the opening the bell, we will be buying 300 shares of Bristol Myers Squibb at roughly $56.50. Following the trade, Jim Cramer’s Charitable Trust will own 1,200 shares of BMY, increasing its weighting in the portfolio to roughly 1.9% from about 1.4%. Wall Street’s stretch of bad breadth may have finally caught up […]
Read More
We want to boost our ownership of a portfolio stock that just boosted its dividend
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Thursday markets: Stocks are taking a breather after Wednesday’s big surge, especially in the Nasdaq Composite and the more narrow “Magnificent Seven” cohort. The yield on […]
Read More
Healthy Returns: Wall Street mulls over Amgen’s weight loss drug data
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Wall Street is chewing over critical […]
Read More
Our newest portfolio stock backed off its recent 52-week high — so we’re buying more
We’re buying 300 shares of Bristol-Myers Squibb at roughly $58 each. Following Wednesday’s trade, Jim Cramer’s Charitable Trust will own 900 shares of BMY, increasing its weighting to about 1.5% from 1%. Shares of pharmaceutical maker Bristol-Myers have dropped about 3% in the past two days in the absence of any real news. The stock […]
Read More
Stocks making the biggest moves midday: AbbVie, Tesla, Cigna, Morgan Stanley and more
Check out the companies making headlines in midday trading. Tesla — The electric vehicle stock popped 7% to build on last week’s 29% gain as investors bet that a Trump administration would fare well for the company and CEO Elon Musk. AbbVie — Shares tumbled 12% after the pharmaceutical company said its experimental schizophrenia drug […]
Read More
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday reported third-quarter earnings and revenue that blew past Wall Street’s expectations thanks to its blockbuster blood thinner Eliquis and a portfolio of drugs […]
Read More